tiprankstipranks
ERYTECH PHARMA (GB:0QSS)
LSE:0QSS
Holding GB:0QSS?
Track your performance easily

ERYTECH PHARMA (0QSS) Income Statement

0 Followers

ERYTECH PHARMA Income Statement

Last quarter (Q4 2022), ERYTECH PHARMA's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, ERYTECH PHARMA's net income was €―. See ERYTECH PHARMA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--€ 4.18M€ 3.72M€ 1.07M-
Cost of Revenue
-€ -33.79M-€ -72.55M€ -69.36M€ -48.07M
Gross Profit
-€ 33.99M-€ 72.80M€ 70.43M€ 48.14M
Operating Expense
€ 29.82M€ 35.16M€ 60.70M€ 77.90M€ 70.89M€ 48.10M
Operating Income
€ -29.82M€ -35.16M€ -60.70M€ -77.90M€ -70.89M€ -48.10M
Net Non Operating Interest Income Expense
€ 3.15M€ 4.45M€ 5.42M€ 889.00K€ 2.95M€ 5.43M
Other Income Expense
€ -2.87M€ -31.00M€ -4.18M€ -3.72M€ -5.28M€ -4.45M
Pretax Income
€ -2.32M€ 293.00K€ -53.80M€ -73.30M€ -62.66M€ -38.22M
Tax Provision
€ 3.84M€ 500.00K€ 2.00K€ 3.00K€ -1.00K€ 2.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -6.16M€ -207.00K€ -53.80M€ -73.30M€ -62.66M€ -38.23M
Basic EPS
€ -0.20€ -0.01€ -2.27€ -3.99€ -3.49€ -2.13
Diluted EPS
€ -0.20€ -0.01€ -2.27€ -3.99€ -3.49€ -2.13
Basic Average Shares
€ 93.05M€ 31.02M€ 23.69M€ 18.39M€ 17.94M€ 17.94M
Diluted Average Shares
€ 93.05M€ 20.70M€ 23.70M€ 18.37M€ 17.95M€ 17.95M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 29.82M€ 1.36M€ 60.70M€ 5.35M€ 1.53M€ 29.00K
Net Income From Continuing And Discontinued Operation
€ -6.16M€ -207.00K€ -53.80M€ -73.30M€ -62.66M€ -38.23M
Normalized Income
€ -4.44M-----
Interest Expense
€ 881.00K-----
EBIT
€ -1.44M€ 293.00K€ -53.80M€ -74.98M€ -62.66M€ -38.22M
EBITDA
€ -1.44M€ 4.91M€ -48.42M€ -69.99M€ -58.44M€ -37.43M
Currency in EUR

ERYTECH PHARMA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis